Kefah Mokbel, Chair of Breast Cancer Surgery at London Breast Institute and Honorary Professor of Medicine at Cardiff University School of Medicine, shared a post on LinkedIn about a recent article by Jeong Hun Oh et al, adding:
“Nearly Half of cN2–3 Breast Cancer Patients Achieve Axillary pCR – Paving the Way for Less Axillary Surgery
The data of this study show that pathologic complete response approaches 50% in patients with cN2–3 breast cancer following neoadjuvant chemotherapy. Predictors include triple-negative or HER2-positive subtypes and radiologic complete response.
These findings highlight that de-escalation of axillary surgery is feasible, potentially sparing half of these patients from extensive surgery and improving quality of life. Precision approaches tailored to tumor biology and imaging can now guide safer, individualized surgical decisions.
An important next question is whether regional nodal irradiation can also be safely de-escalated in this subgroup (cN2-3 → ypN0), since the B-51 trial only included cN1 patients. Personalized strategies based on tumor biology and imaging are increasingly shaping safer, tailored treatment.”
Title: Nomogram for predicting axillary pathologic complete response in cN2–3 breast cancer after neoadjuvant chemotherapy
Authors: Jeong Hun Oh, Soyeon Ahn, Mijung Jang, Yena Yoon, Seongjin Jeong, Jongwon Kang, Hyoung Won Koh, Kyung-Hwak Yoon, Hee-Chul Shin, Eun-Kyu Kim
Read the Full Article on npj breast cancer
More posts featuring Kefah Mokbel.
